awmsg logo



lubiprostone (Amitiza®)


Reference No. 1910

Publication date:
23/01/2013


Appraisal information

lubiprostone (Amitiza®) 24 micrograms capsule


Company: Sucampo Pharma
BNF category: Gastro-intestinal system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Superseded
Advice No: Not available
Ratification by Welsh Government: 16/01/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA318) NICE GUIDANCE ISSUED JULY 2014 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). In the absence of a submission from the holder of the marketing authorisation, lubiprostone (Amitiza®) cannot be endorsed for use within NHS Wales for the treatment of chronic idiopathic constipation and associated symptoms in adults.
Statement of Advice (SOA)
Download